{
    "clinical_study": {
        "@rank": "11701", 
        "arm_group": [
            {
                "arm_group_label": "1 BI 1181181 single rising dose part", 
                "arm_group_type": "Experimental", 
                "description": "single rising doses of BI 1181181"
            }, 
            {
                "arm_group_label": "2 BI 1181181 bioavailability part", 
                "arm_group_type": "Experimental", 
                "description": "bioavailability, food effect part of BI 11881181"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the safety, tolerability, pharmacokinetics (including dose proportionality\n      assessment), and pharmacodynamics of single rising oral doses of BI 1181181 (Single rising\n      dose (SRD) part) Secondly, to investigate the relative bioavailability of the tablet versus\n      the powder for oral solution (PfOS) and the effect of food on the pharmacokinetics of BI\n      1181181 (Bioavailability/Food effect (BA/FE) part)"
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy males according to the investigator's assessment, as based on the following\n             criteria: a complete medical history including a physical examination, vital signs\n             blood pressure (BP), pulse rate (PR), 12-lead ECG, and clinical laboratory tests\n\n          -  Age 18 to 50 years (incl.)\n\n          -  Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.)\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation\n\n        Exclusion criteria:\n\n          -  Any finding in the medical examination (including BP, PR or ECG) deviating from\n             normal and judged clinically relevant by the investigator\n\n          -  Repeated measurement of systolic blood pressure < 90 mmHg and >= 140 mmHg at\n             screening\n\n          -  Repeated measurement of diastolic blood pressure < 55 and >= 90 mmHg at screening\n\n          -  Repeated measurement of pulse rate < 50 bpm and > 90 bpm at screening\n\n          -  Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          -  Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044406", 
            "org_study_id": "1344.1", 
            "secondary_id": "2013-002868-88"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 BI 1181181 single rising dose part", 
                "description": "single dose (low to high dose)", 
                "intervention_name": "BI 1181181", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 BI 1181181 bioavailability part", 
                "description": "powder for oral solution", 
                "intervention_name": "BI 1181181, R", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 BI 1181181 bioavailability part", 
                "description": "tablet, fasted", 
                "intervention_name": "BI 1181181, T2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1 BI 1181181 single rising dose part", 
                "description": "Placebo to BI 1181181", 
                "intervention_name": "Placebo to BI 1181181", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 BI 1181181 bioavailability part", 
                "description": "tablet, fed", 
                "intervention_name": "BI 1181181, T1", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingelheim", 
                    "country": "Germany"
                }, 
                "name": "1344.1.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability and the Effect of Food on the Pharmacokinetics of BI 1181181(Open-label, Randomised, Three-way Cross-over Design)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number (%) of subjects with drug-related adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044406"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Aet1-t2 (Amount of analyte that is eliminated in urine from the time point t1 to timepoint t2 after single dose administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "tmax (time from dosing to maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "t1/2 (terminal half-life of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}